Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04343248 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
A Phase 3 study, sponsored by Romark Laboratories L.C..
- Terminated
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
NCT04343248: Clinical Trial Phase 3 study, sponsored by Romark Laboratories L.C..
NCT04343248 is a Phase 3 study that was terminated before completion, run by Romark Laboratories L.C.. The registered enrollment target is 190 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04343248, a Phase 3 study, was terminated before completion, sponsored by Romark Laboratories L.C..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
Study Summary
Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF residents.
Primary Outcome
The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period. NOTE: No statistical analyses were performed as enrollment was terminated early. See caveats and limitations.
Interventions
- DRUG Placebo
- DRUG Nitazoxanide
- DIETARY_SUPPLEMENT Vitamin Super B-Complex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2020-05-12 |
| Est. Completion | 2021-02-01 |
| Phase | Phase 3 |
Why NCT04343248 stopped before completion
NCT04343248 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04343248 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04343248 about?
NCT04343248 is a clinical study titled "Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)". Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF residents.
What is the current status of trial NCT04343248?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2020-05-12. Estimated completion is 2021-02-01.
What interventions are being tested in trial NCT04343248?
The interventions under investigation include: Placebo (DRUG), Nitazoxanide (DRUG), Vitamin Super B-Complex (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04343248?
This trial is sponsored by Romark Laboratories L.C., which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04343248's enrollment target sits among peer trials
190 1402nd of 2000 higher than 593 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI